The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet?

Shepherd, Scott T C; Drake, William M; Turajlic, Samra

Shepherd, Scott T C; Drake, William M; Turajlic, Samra.

Affiliation

Shepherd STC; Cancer Dynamics Laboratory, The Francis Crick Institute, Midland Road, London, UK; Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London, UK.
Drake WM; Department of Endocrinology, St. Bartholomew's Hospital, London, UK.
Turajlic S; Cancer Dynamics Laboratory, The Francis Crick Institute, Midland Road, London, UK; Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London, UK. Electronic address: samra.turajlic@crick.ac.uk.

Eur J Cancer ; 182: 15-22, 2023 03.

Article in En | MEDLINE | ID: mdl-36708612

Subject(s)
Key words

Belzutifan; Hereditary cancer syndrome; VHL disease

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Neuroectodermal Tumors, Primitive / Von Hippel-Lindau Disease / Kidney Neoplasms Aspects: Patient_preference Limits: Humans Language: En Journal: Eur J Cancer Year: 2023 Document type: Article Affiliation country: Reino Unido Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google